News | November 21, 2023

Myricx Bio Enters Into An Exclusive Antibody License Agreement With Wuxi Biologics

WuXi Biologics (“WuXi Bio”) a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Myricx Bio (“Myricx”), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), today announced that they have entered into a license agreement under which Myricx will have exclusive access to a proprietary antibody that was discovered based on WuXi Bio’s integrated technology platforms.

Under the terms of the agreement, Myricx will develop the antibody into a first-in-class ADC based on its NMTi payload platform, which has a highly differentiated profile over standard payload classes, including microtubule and topoisomerase inhibitors. Myricx intends to progress the ADC through preclinical and clinical development for difficult-to-treat solid tumours. WuXi Bio will receive an upfront payment and will be eligible for development and commercialisation milestone payments, as well as royalties on net sales.

Dr. Chris Chen, CEO of WuXi Biologics, commented, “This license agreement with Myricx is another testament of our proprietary integrated platform and the ‘R’ in our CRDMO business model. We are looking forward to enabling global clients to develop more first-in-class and best-in-class biologics drugs for the benefits of patients worldwide.”

Dr. Robin Carr, CEO of Myricx, commented, “We are delighted to have reached this agreement with WuXi Bio, one of the top biologics CRDMOs globally. We believe that combining this leading antibody with our novel NMTi-based payload will create an ADC with significant clinical differentiation in solid tumours. Based on our positive preclinical data we believe NMTi-ADCs offer a highly differentiated mechanism of action, superb efficacy and good tolerability across different cancer targets.”

WuXi Biologics offers a full spectrum of end-to-end and modular discovery services from idea to preclinical candidate identification using industry leading technology platforms and comprehensive discovery capabilities. Its discovery technology platforms for the generation, characterization, engineering, optimization and selection of novel antibody and biologic therapeutics include hybridoma technology, single B cell cloning technology, phage display and yeast display technology, immune and synthetic human scFv and VHH libraries, the human IgG transgenic platforms through OmniAb and Alloy partnership, bispecific antibody platforms represented by the WuXiBody and SDarBody, and other antibody and biologics generation and optimization technologies. All technology platforms are supported by the company’s comprehensive research material generation and assay development capabilities.

Source: WuXi Biologics